Latest News about CNCR
Recent news which mentions CNCR
As U.K. Authorizes Pfizer Vaccine, Biotech ETFs Continue to Rally
December 03, 2020
From ETF Trends
ETF Wrap: Size doesn’t matter
December 03, 2020
From MarketWatch
How Will Vaccine Arrivals Affect Biotech ETFs?
November 30, 2020
From ETF Trends
Biotech ETFs Remain Hot As Investors Await Upcoming Vaccine
November 27, 2020
From ETF Trends
Biotech ETFs Poised for Gains after Moderna Vaccine News
November 16, 2020
From ETF Trends
Will Moderna Vaccine News Boost Biotech ETFs?
November 12, 2020
From ETF Trends
From MarketWatch
ETF Wrap: How to think about – and play – the wave of M&A activity
September 17, 2020
From MarketWatch
Moderna Vaccine Optimism Could Drive Biotech ETFs
August 26, 2020
From ETF Trends
U.S. Rejects Help From Russia In Race For Viable Vaccine
August 17, 2020
From ETF Trends
From ETF Trends
From ETF Trends
What Are The Sectors for a “New Economy?”
May 22, 2020
From ETF Trends
From ETF Trends
3 ETFs For More Moderna Bets
May 19, 2020
From Benzinga
Biotech ETFs Strengthen as Amgen Invests in China’s BeiGene
November 01, 2019
From ETF Trends
How to Invest in Cancer-Fighting Stocks
July 23, 2019
From Motley Fool
These 3 revolutionary genomics companies are changing lives for patients — and investors
May 09, 2019
From MarketWatch
From ETF Trends
Specialized Biotech ETF Rallies on MacroGenics Positive Trial Results
February 06, 2019
From ETF Trends
Hone In On Health Care In China With This New ETF
August 16, 2018
From Benzinga
March Madness for ETFs: 10 Funds Leading the Pack
March 09, 2018
From ETF Trends
Bristol-Myers touts lung cancer breakthrough, but critics cry foul
February 05, 2018
From MarketWatch
Biotech ETFs Pop on Celgene, Juno Deal
January 22, 2018
From ETF Trends
Merck leaps past rivals with latest lung cancer drug results
January 16, 2018
From MarketWatch
Cancer vaccines, long considered failures, are hot again
September 15, 2017
From MarketWatch
Biotech ETFs Jump on Gilead, Kite Deal
August 28, 2017
From ETF Trends
From MarketWatch
Cancer drug prices could double or triple thanks to this popular but unproven drug trend
June 01, 2017
From MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.